HC Wainwright Issues Positive Estimate for Cybin Earnings

Cybin Inc. (NASDAQ:HELP) – Analysts at HC Wainwright increased their Q2 2027 EPS estimates for Cybin in a research note issued to investors on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.67) per share for the quarter, up from their previous forecast of ($0.80). The consensus estimate for Cybin’s current full-year earnings is ($3.23) per share. HC Wainwright also issued estimates for Cybin’s Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.59) EPS, FY2027 earnings at ($2.78) EPS, Q1 2028 earnings at ($0.59) EPS, Q2 2028 earnings at ($0.53) EPS, Q3 2028 earnings at ($0.53) EPS, Q4 2028 earnings at ($0.54) EPS, FY2028 earnings at ($2.19) EPS, FY2029 earnings at ($1.09) EPS, FY2030 earnings at $0.62 EPS and FY2031 earnings at $3.78 EPS.

Cybin (NASDAQ:HELP) last posted its earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11).

Other equities analysts also recently issued research reports about the company. TD Cowen increased their price target on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company began coverage on shares of Cybin in a research note on Monday, July 27th. They issued an “overweight” rating and a $16.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $48.60.

Cybin Stock Performance

HELP opened at $12.47 on Friday. The firm has a market cap of $911.06 million, a P/E ratio of -4.13 and a beta of 0.55. The business has a 50 day moving average price of $7.66 and a 200 day moving average price of $6.20. Cybin has a twelve month low of $3.76 and a twelve month high of $12.72.

Institutional Investors Weigh In On Cybin

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its position in Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after acquiring an additional 959,448 shares during the period. Osaic Holdings Inc. raised its stake in Cybin by 46.7% during the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after purchasing an additional 2,400 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after purchasing an additional 11,790 shares during the period. Institutional investors and hedge funds own 17.94% of the company’s stock.

Key Stories Impacting Cybin

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: TD Cowen raised its price target from $8 to $62 and assigned a “buy” rating, implying substantial potential upside from Cybin’s recent trading level. The aggressive target increase appears to be the primary catalyst behind investor interest. HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
• Positive Sentiment: HC Wainwright improved several longer-term earnings forecasts. Its FY2027 loss estimate narrowed to $2.78 per share from $2.96, while FY2029 losses narrowed to $1.09 from $1.20. The firm also raised projected profitable earnings for FY2030 to $0.62 from $0.36 and FY2031 to $3.78 from $3.23, suggesting greater confidence in Cybin’s eventual commercialization and profitability potential. Cybin Price Target Raised by TD Cowen
• Positive Sentiment: HC Wainwright also raised its Q2 2027 and Q3 2027 EPS forecasts to losses of $0.67 and $0.68, respectively, from $0.80 losses, and modestly improved its Q1 and Q4 2028 estimates.
• Neutral Sentiment: The updated forecasts still call for substantial losses in the near and medium term. The current full-year consensus remains a loss of $3.23 per share, and Cybin’s recent quarterly loss of $0.91 per share missed the $0.80 consensus estimate.
• Negative Sentiment: HC Wainwright lowered its FY2028 EPS forecast to a $2.19 loss from a $2.09 loss and reduced estimates for Q2, Q3 and Q4 2028. These revisions indicate that the path to profitability could take longer than previously expected.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.